Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL661063 | 1.00 | SLC34A1 (0.55) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL29222246 | 1.00 | SLC34A1 (0.55) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL252341 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL8620684 | 1.00 | SLC34A1 (0.55) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL152268 | 1.00 | SLC34A1 (0.55) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL735694 | 1.00 | SLC34A1 (0.55) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL982197 | 1.00 | SLC34A1 (0.55) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL735689 | 1.00 | SLC34A1 (0.55) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL23722691 | 0.94 | SLC34A1 (0.50) | SLC34A1LMNA | |
| Phosphoric Acid SCHEMBL2901169 | 0.94 | SLC34A1 (0.50) | SLC34A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025103475-A1 | HETEROCYCLIC CARBONYL DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-05-22 | — | — | WO | claimed |
| CN-118994109-A | Preparation method of lysine-specific demethylase 1 inhibitor | 成都苑东生物制药股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-117720521-A | Salt of nitrogen-containing heterocyclic ketone compound and preparation method thereof | 江苏豪森药业集团有限公司 | 2024-03-19 | — | — | CN | claimed |
| EP-3589276-B9 | STARCH-FREE SOFT CHEW FOR VETERINARY APPLICATIONS | TGX SOFT CHEW LLC (US) | 2024-01-17 | — | — | EP | claimed |
| EP-3589276-B1 | STARCH-FREE SOFT CHEW FOR VETERINARY APPLICATIONS | TGX SOFT CHEW LLC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-111138413-B | Preparation method of cyclin-dependent kinase inhibitor and intermediate thereof | 江苏豪森药业集团有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-111138413-A | Preparation method and intermediate of cyclin-dependent kinase inhibitor | 江苏豪森药业集团有限公司 | 2020-05-12 | — | — | CN | claimed |
| US-20170273932-A1 | LYOPHILIZED COMPOSITIONS CONTAINING A METAP-2 INHIBITOR | ZAFGEN INC (US) | 2017-09-28 | — | — | US | claimed |
| EP-3182960-A1 | LYOPHILIZED COMPOSITIONS CONTAINING A METAP-2 INHIBITOR | Zafgen, Inc. (US) | 2017-06-28 | — | — | EP | claimed |
| WO-2016029206-A1 | LYOPHILIZED COMPOSITIONS CONTAINING A METAP-2 INHIBITOR | ZAFGEN, INC. (US) | 2016-02-25 | — | — | WO | claimed |
| JP-62292609-A | — | — | None | — | — | JP | disclosed |
| US-12365927-B2 | Engineered ketoreductase polypeptides | CODEXIS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025103475-A1 | HETEROCYCLIC CARBONYL DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| CN-119753032-A | Method for producing hydrogen and electricity by using biomass | 东莞理工学院 | 2025-04-04 | — | — | CN | disclosed |
| CN-119039223-B | Preparation method of nitrogen-containing heteroaromatic derivative and intermediate thereof | 江苏豪森药业集团有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-5194246-A | Anionic telomers modified by sodium hypophosphite, blend of low and high molecular weight polymers | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1993-03-16 | — | — | US | disclosed |
| EP-0518395-A2 | Anticalculus oral compositions containing combinations of polymers | UNILEVER N.V. (NL) | 1992-12-16 | — | — | EP | disclosed |
| EP-0509570-A1 | Combination of hypophosphite-containing cotelomers and inorganic polyphosphate salts as anticalculus oral compositions | UNILEVER N.V. (NL) | 1992-10-21 | — | — | EP | disclosed |
| US-5143719-A | ANTICALCULUS ORAL COMPOSITION CONTAINING COMBINATIONS OF ORGANOPHOSPHORUS POLYCARBOXYLATE COTELOMERS AND INORGANIC POLYPHOSPHATE SALTS | CHESEBROUGH-POND'S USA CO. (US) | 1992-09-01 | — | — | US | disclosed |
| JP-S62292609-A | MANUFACTURE OF POTASSIUM DIHYDRATE PHOSPHATE | HAIFA CHEMICALS LTD | 1987-12-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273932-A1 | LYOPHILIZED COMPOSITIONS CONTAINING A METAP-2 INHIBITOR | METAP2, CETP, PMM2 | SLC34A1 1930/4885LMNA 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.